Medication info

Empagliflozin and Metformin Tablets 5/500 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Orange-yellow, bilaterally convex oval film-coated tablets
Packaging
10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/box [(10 tablets/PTP x 6)], 60 tablets/bottle
Approval status
Active

MFDS item code 202201443 · Approved 2022.04.05

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this drug is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended dose when taking this drug is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional blood glucose control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this drug from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this drug is coadministered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions in Precautions for Use). This drug should be taken with food to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this drug is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. No dose adjustment is necessary in patients with mild renal impairment. Because this drug contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other symptoms that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this drug is 1000 mg, which may be given as 500 mg twice daily. Renal function should be closely monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Receive This Drug, item 2)). In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood sugar control abnormalities
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. It is particularly effective in adult patients who are suitable for dual therapy with empagliflozin and metformin. Furthermore, if adult patients with type 2 diabetes have not had sufficient blood sugar control, especially those with confirmed cardiovascular disease, it should be used with caution according to clinical trial information. This medication helps manage blood sugar effectively for diabetes treatment.

How to take

Adult dose

The recommended dose of this drug is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended dose when taking this drug is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional blood glucose control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this drug from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this drug is coadministered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions in Precautions for Use). This drug should be taken with food to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this drug is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. No dose adjustment is necessary in patients with mild renal impairment. Because this drug contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other symptoms that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this drug is 1000 mg, which may be given as 500 mg twice daily. Renal function should be closely monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Receive This Drug, item 2)). In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication can cause a rare but serious side effect known as lactic acidosis, therefore it should not be used in patients with poor kidney function, acute kidney issues, severe infections, or dehydration. Additionally, the risk of hypoglycemia may increase if this medication is used in conjunction with insulin or sulfonylureas, so blood sugar levels should be monitored carefully in such cases. It is best to avoid this medication in pregnant women or those who may become pregnant, breastfeeding mothers, and patients with severely impaired liver function. Since this medication is influenced by kidney function, regular kidney function tests should be performed before and during treatment, and the medication should be discontinued if kidney function falls below a certain level. Before and after procedures utilizing iodinated contrast media, this medication should be temporarily discontinued, and resumed only after kidney function has returned to normal. This medication can lead to fluid loss, so it should be used carefully in elderly patients, those with low blood pressure, or symptoms of dehydration, with the option to interrupt treatment if necessary. During treatment, urinary tract infections or genital infections may occur, thus any infections should be reported to healthcare professionals immediately. Since vitamin B12 levels may decrease, it is advisable to check blood vitamin B12 levels in patients receiving long-term treatment. It is crucial to avoid alcohol consumption while taking this medication, and be cautious of irregular eating habits or excessive exercise, as well as potential interactions with other medications that may increase the risk of hypoglycemia or ketoacidosis. Elderly patients have a higher risk of renal function decline and fluid loss; therefore, dosage adjustments and regular monitoring are necessary during treatment. In the event of an overdose of this medication, it is essential to seek medical attention promptly, especially if symptoms of lactic acidosis occur, as immediate emergency treatment is required.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 166 more
  • abnormal liver function tests
  • hepatitis
  • altered taste sensation
  • itching
  • rash
  • hives
  • erythema
  • angioedema
  • difficulty urinating
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • ketosis
  • lactic acidosis
  • decreased fluid volume
  • perineal necrosis
  • vulvar moniliasis
  • vaginitis
  • balanitis
  • ear and labyrinth disturbance
  • otalgia
  • positional vertigo
  • dizziness
  • headache
  • lightheadedness
  • drowsiness
  • facial paralysis
  • memory disturbances
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • sensory disturbances
  • CNS-origin vertigo
  • weakness
  • chest discomfort
  • chest pain
  • fever
  • chills
  • unusual sensations
  • edema
  • pain
  • pain at the site of puncture
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • cerebral infarction
  • soft tissue inflammation
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic carcinoma
  • insomnia
  • anxiety
  • depression
  • sleep disorders
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colon bleeding
  • appendiceal abscess
  • appendicitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • shingles
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureteral calculi
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urine retention
  • urinary pain
  • abnormal urination
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • ocular discomfort
  • ocular congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • serous retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • cough
  • epistaxis
  • allergic rhinitis
  • skin laceration
  • rib fracture
  • long ligament syndrome
  • angina
  • palpitations
  • Prinzmetal's angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container, ensuring it does not come into contact with air or moisture, and keep it at a safe temperature between 1 degree and 30 degrees Celsius. Storing it this way can help maintain its efficacy for a longer duration.

Appearance and packaging

Appearance

Orange-yellow, bilaterally convex oval film-coated tablets

Package unit

10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/box [(10 tablets/PTP x 6)], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.